ClinicalTrials.gg
Not yet recruitingNCT07742579Updated Aug 3, 2026

Online Mindfulness-Based Cognitive Therapy for People With Multiple Sclerosis With Mild-Moderate Depression

A Phase 3 interventional study of Mindfulness-Based Cognitive Therapy in Multiple Sclerosis, sponsored by Robert Simpson. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Robert Simpson · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will use a waiting list randomized controlled trial design with a mixed-methods research approach, including both quantitative and qualitative methods. Randomization helps minimize research bias and controls for participant and contextual factors that might otherwise make interpretation of results challenging. We will recruit 152 people with multiple sclerosis (PwMS) with any type of MS, who also have mild-moderate depression, aged 18 or greater, and able to understand spoken and written English.

For the quantitative part, we will examine how much change in depression there is following mindfulness-based cognitive therapy (MBCT), as well as whether participants attend the course and complete study measures or not, and how much participants complete MBCT home practices. We will also examine how much change there is in fatigue, sleep pain, quality of life, and anxiety.

For the qualitative part of the study, we will use semi-structured interviews to explore participant experiences of online MBCT, how people used online MBCT, what worked, what didn't and why, how online MBCT impacted self-management of depression, and suggestions for improving the course to make it more relevant for PwMS with depression.

02

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • mindfulness
  • Mindfulness-Based Cognitive Therapy
03

In context

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

This study's planned enrollment of 152 is above the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.

Browse Multiple Sclerosis studies →

Lead sponsor

Robert Simpson is the lead sponsor of 5 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >/=18
  • Neurologist confirmed MS diagnosis (McDonald criteria)
  • Able to understand spoken and written English
  • A score of 14-28 on the Beck Depression Inventory-II signifying mild-moderate depression
  • Registered with a primary care provider (family physician or neurologist)
  • Residing in Canada

Exclusion criteria

Exclusion criteria will include:

  • Potentially life-threatening comorbidities (suicidal ideation (i.e., score of 2 or 3 on the BDI-Fast Screen suicidal ideation question), history of psychosis, terminal/life threatening inter-current illness), or those such conditions expected to significantly limit participation and adherence (pregnancy, cognitive impairment i.e. score \<26 on the - MoCA)
  • Receipt of MBCT in the past 2 years (completed at least 4/8 sessions).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
152 participants (estimated)

Study arms

  • Experimental
    Mindfulness-Based Cognitive Therapy

    Online group Mindfulness-Based Cognitive Therapy delivered live online in weekly sessions for 8 weeks

    Other: Mindfulness-Based Cognitive Therapy

  • No intervention
    Waitlist control

    Waitlist control arm - participants receive no intervention initially but receive MBCT following data collection

Interventions

  • OtherMindfulness-Based Cognitive Therapy

    Online group Mindfulness-Based Cognitive Therapy delivered live online in weekly sessions for 8 weeks

06

What researchers measure

Primary outcomes

  1. Depression

    Change in depression scores using the Hospital Anxiety and Depression Scale

    Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)

Secondary outcomes

  1. Self-efficacy

    Self-efficacy, as measured by the Generalized Self-Efficacy Scale

    Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)

  2. Self-management

    Self-management, as measured by the Multiple-Sclerosis Self-Management Scale-Revised

    Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)

  3. Stigma

    Stigma, as measured by the Stigma Scale for Chronic Illness-8

    Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)

  4. Fatigue

    Fatigue as measured by the Modified Fatigue Impact Scale

    Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)

  5. Sleep

    Sleep as measured by the Insomnia Severity Index

    Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)

  6. Change in pain

    Pain as measured by the Pain Effects Scale

    Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)

  7. Change in quality of life

    Quality of life as measured by the Multiple Sclerosis Impact Scale-29

    Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)

  8. Anxiety

    Anxiety as measured by Hospital Anxiety and Depression Scale -Anxiety

    Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)

  9. Mindfulness

    Mindfulness as measured by The Five-facet Mindfulness Questionnaire

    Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)

  10. Self-compassion

    Self-compassion, measured using the The Self-Compassion Scale-short form

    Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)

  11. Emotion regulation

    Emotion regulation, as measured by The Difficulties with Emotional Regulation Scale short-form

    Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)

  12. Group attendance

    Group attendance in those allocated to tailored online MBCT

    Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)

  13. Group climate

    Group climate using the Climate Questionnaire-Engage Scale

    Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)

  14. Therapeutic alliance

    Therapeutic alliance as measured by the Working Alliance Inventory

    Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)

  15. Depressive symptoms

    Depressive symptoms as measured by the Beck Depression Inventory II (BDI-II)

    Time frame: Baseline (T0), immediately post MBCT (T1), and 3 months later (T2)

  16. Implementation

    Implementation, as informed by the Proctor's taxonomy

    Time frame: Throughout the study and up to 12 months post-intervention

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Nov 2028, 27 months later.

Of 96 phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 63. This study's planned 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2026
First posted
Aug 3, 2026
StartEst.
Aug 2026
Primary completionEst.
Nov 2028
CompletionEst.
Dec 2028
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07742579
Lead sponsor
Robert Simpson
Responsible party
Robert Simpson (Associate Professor, University of Toronto) — Sponsor-investigator
First posted
Aug 3, 2026
Start date
Aug 2026 (estimated)
Primary completion
Nov 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Aug 3, 2026

Study contacts

Robert Simpson
Contact
rab.simpson@utoronto.ca
416-978-8383

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion